Karthik Kuppusamy Sells 1,760 Shares of Quest Diagnostics Incorporated (NYSE:DGX) Stock

Quest Diagnostics Incorporated (NYSE:DGX) SVP Karthik Kuppusamy sold 1,760 shares of the stock in a transaction on Monday, April 29th. The shares were sold at an average price of $140.00, for a total value of $246,400.00. Following the sale, the senior vice president now owns 13,435 shares of the company’s stock, valued at approximately $1,880,900. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Quest Diagnostics Stock Down 0.9 %

Shares of DGX opened at $136.34 on Friday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.89 and a current ratio of 0.97. The firm has a market capitalization of $15.15 billion, a P/E ratio of 18.35, a P/E/G ratio of 3.00 and a beta of 0.88. Quest Diagnostics Incorporated has a 52 week low of $119.59 and a 52 week high of $145.58. The company has a 50-day simple moving average of $130.13 and a 200-day simple moving average of $131.61.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.86 by $0.18. The business had revenue of $2.37 billion for the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a return on equity of 15.52% and a net margin of 9.11%. The firm’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.04 earnings per share. On average, equities research analysts expect that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of DGX. Czech National Bank boosted its holdings in shares of Quest Diagnostics by 0.4% during the fourth quarter. Czech National Bank now owns 19,692 shares of the medical research company’s stock worth $2,715,000 after acquiring an additional 75 shares during the period. Mendota Financial Group LLC raised its stake in Quest Diagnostics by 6.2% in the fourth quarter. Mendota Financial Group LLC now owns 1,296 shares of the medical research company’s stock valued at $179,000 after purchasing an additional 76 shares in the last quarter. Arkadios Wealth Advisors lifted its position in Quest Diagnostics by 1.6% during the first quarter. Arkadios Wealth Advisors now owns 4,933 shares of the medical research company’s stock worth $657,000 after purchasing an additional 77 shares during the period. New England Capital Financial Advisors LLC lifted its position in shares of Quest Diagnostics by 24.7% during the 1st quarter. New England Capital Financial Advisors LLC now owns 389 shares of the medical research company’s stock worth $52,000 after buying an additional 77 shares during the last quarter. Finally, Exchange Traded Concepts LLC increased its holdings in shares of Quest Diagnostics by 1.9% during the third quarter. Exchange Traded Concepts LLC now owns 4,417 shares of the medical research company’s stock worth $538,000 after buying an additional 84 shares in the last quarter. 88.06% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on DGX. Jefferies Financial Group raised Quest Diagnostics from a “hold” rating to a “buy” rating and boosted their target price for the stock from $140.00 to $155.00 in a research report on Wednesday, February 7th. SVB Leerink assumed coverage on Quest Diagnostics in a research note on Monday, February 26th. They set a “market perform” rating and a $135.00 price target for the company. Citigroup lifted their price objective on shares of Quest Diagnostics from $135.00 to $145.00 and gave the company a “neutral” rating in a research note on Wednesday, April 24th. Truist Financial upped their target price on Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, April 24th. Finally, Mizuho lifted their price target on shares of Quest Diagnostics from $150.00 to $155.00 and gave the company a “buy” rating in a research report on Wednesday, April 24th. Ten research analysts have rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Hold” and an average price target of $146.17.

About Quest Diagnostics

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.